<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608799</url>
  </required_header>
  <id_info>
    <org_study_id>201802018RIND</org_study_id>
    <nct_id>NCT04608799</nct_id>
  </id_info>
  <brief_title>The Efficacy of Fycompa (Perampanel) in Children With Epilepsy</brief_title>
  <official_title>Director of Child Neurology, Department of Pediatrics, National Taiwan University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fycompa (Perampanel), a new anti-epileptic drug that uses a new mechanism-AMPA receptor&#xD;
      antagonist. Its initial indication is for local or generalized epilepsy in children and&#xD;
      adults over 12 years old, but its effectiveness in the treatment of epilepsy in children At&#xD;
      present, more evidence is still needed. We will study the effectiveness of Fycompa&#xD;
      (Perampanel) in the treatment of epilepsy in children under the age of 18. It is expected&#xD;
      that the clinical use of Fycompa (Parampanel) in Taiwan will be able to analyze and study the&#xD;
      effectiveness of the clinical use of Fycompa (Parampanel) in the treatment of epilepsy in&#xD;
      children, and compare it with foreign reports.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">March 19, 2020</completion_date>
  <primary_completion_date type="Actual">March 19, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of perampanel in young children with drug-resistant epilepsy</measure>
    <time_frame>17 years</time_frame>
    <description>Because the current clinical research data on the use of Fycompa (perampanel) in children for the treatment of epilepsy is still insufficient, the purpose of this research is to review the efficacy of this drug in the treatment of children with epilepsy in our hospital in the past, so as to facilitate the future clinical treatment of children with epilepsy. Children have the possibility of therapeutic reference.</description>
  </primary_outcome>
  <enrollment type="Actual">38</enrollment>
  <condition>Neurologic Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perampanel</intervention_name>
    <description>Efficacy of epilepsy drugs</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from epilepsy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years of age suffering from epilepsy&#xD;
&#xD;
          -  Patients who are taking Paraampanel&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are not in the above age groups and who are not using parampanel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WangTso Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

